This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Index levels influence expectations and decisions in markets. Here are core reasons they matter and how to leverage them in trading.
24,028 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Analysts warn that the CLARITY Act's odds of passing have fallen below 50% as the Senate's August recess approaches. ...
Wells Fargo offers a cheaper entry and higher yield than Bank of America, delivering more bang your buck for income-f...
Three iShares ETFs have jumped more than 100% in 2026, led by chip-rich South Korea and Taiwan. This article breaks d...
As AI infrastructure expands beyond GPUs, investors ask whether Nvidia is undervalued or overvalued — or perhaps both...
A new collaboration between TSMC and Winbond intends to ease DRAM bottlenecks for AI workloads. It’s framed by analys...
Sen. Mitch McConnell remains hospitalized as Republicans grapple with a slim Senate majority ahead of the November mi...
Robinhood has faced challenges, but early signs point to a potential comeback. This guide breaks down what to watch, ...
A retiree’s hesitation to touch a Roth IRA for fear of higher Medicare costs and Social Security taxes is untrue: qua...
Berkshire Hathaway’s cash pile nears the $400 billion mark, renewing scrutiny on what the conglomerate will do with v...
An official says Trump is not expected to veto the housing bill, signaling a potential policy path. Markets are weigh...
A 61-year-old worker loses her job and learns the Social Security estimate may be overstated because of a hidden assu...